Buradasınız

Anasayfa » Content

Kronik Böbrek Hastalığında Endotel Disfonksiyonu: Adiponektin ve İnflamasyonun Rolü

Endothelial Dysfunction in Chronic Kidney Disease: The Role of Adiponectin and Inflammation

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2007

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Aim: Endothelial dysfunction and inflammation are among the leading causes of cardiovascular morbidity and mortality in chronic kidney disease (CKD). Adiponectin is an anti-inflammatory protein. There is no data about the relation between adiponectin, hsCRP and endothelial function in CKD. We aimed to investigate the relation between plasma adiponectin, hsCRP levels and endothelial dysfunction in CKD. Materials and Methods: One hundred patients with CKD were studied. Patients were divided into 5 groups according to their GFR as assesed by K/D0QI guidelines. Twenty-five healthy subjects were studied as controls. Venous samples were obtained from all subjects and taken for adiponectin and hsCRP levels in addition to detailed metabolic panel. Endothelial function was assessed from all subjects by FMD and NMD. Results: Plasma adiponectin levels of stage 1 CKD group were similar to those of the controls, while other groups had significantly higher values (p<0.001). Additionally, hsCRP levels were significantly increased in all stages of CKD. Endothelial dysfunction as assessed by FMD levels were significantly decreased in all stages. The higher the stage of CKD, the lower the levels of FMD. Discussion: The results show that both plasma adiponectin and hsCRP levels are associated with endothelial dysfunction in CKD patients.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Endotel disfonksivonu ve inflamasyon kronik böbrek hastalığında (KBH} kardiyovasküler mortalite ve morbiditeye yol açan nedenler arasındadır. Adiponektin antiinflamatuar bir proteindir. Kronik böbrek hastalığında endotel fonksiyonu ve adiponektin, hsCRP arasındaki ilişki hakkında bilgi yoktur. Bizim amacımız, kronik böbrek hastalığında endotel disfonksiyonu ile plazma adiponektin, hsCRP arasındaki İlişkiyi araştırmaktır. Gereç ve Yöntem: Kronik böbrek hastalıklı 100 hasta çalışmaya alındı. Hastalar K/D0QI kılavuzunda belirlenen glomerüler filt-rasyon değerine (GFD) göre 5 gruba ayrılmıştır. Kontrol olarak 25 sağlıklı kişi çalışılmıştır. Çalışmaya alınan tüm kişilerden venöz kan örneği alınmış ve detaylı metabolik panele ilaveten adiponektin ve hsCRP için de kan örnekleri alınmıştır. Sonuçlar: Endotel fonksiyonu çalışmaya katılan tüm kişilerden elde edilen endotel bağımlı vazodilatasyon (EBVD) ve nitrogliserin aracılı vazodilatasyon değerleri ile değerlendirilmiştir. Evre 1 KBH olanlardaki plazma adiponektin düzeyi kontrol grubuna benzer iken diğer evre KBH olanların düzeyleri belirgin olarak daha yüksekti |p<0.001). İlave olarak hsCRP seviyeleri KBH'nin tüm evrelerinde belirgin olarak artmaktaydı. Endotel disfonksiyonunun belirteci olan EBVD butun evrelerde belirgin olarak azalmaktaydı. Kronik böbrek hastalığının evresi ilerledikçe, EBVD değeri de o kadar azalmaktaydı. Tartışma: Sonuçlar, kronik böbrek hastalığında endotel disfonksiyonunun hem plazma adiponektin hem de hsCRP düzeyleriyle ilişkili olduğunu göstermektedir.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_16_pp_54-62.pdf
  • 2
54-62
  • Turkish

REFERENCES

References: 

1. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative .stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004;65(6):2279-22K9.
2. Annuk M, Söveri I, Zilmer M, Lind L, Hulrhe J, Fellstrom B. Endothelial function, CRP and oxidative stress in chronic kid-
9 Endothelial Dysfunction in Chronic Kidney Disease: The Role of Adiponectin and Inflammation
nyy disease. J Nephrol 2005;18((>):721-726.
3. Yoniccsu VI, Yilmaz Ml. Cilalar K, et al. Blockade of the renin-angiotensin system increases plasma adiponectin levels in rype-2 diabetic patients wilh proteinuria. Nephron Clin Pftiel 2005;09( 4>:c1 IS.121.
i. Yilmaz Ml, Sönmez A, Aeikcl C, el al. Adiponectin may play a part in the pathogenesis of diabetic: retinopathy. Eur J En-tJucrinol 2UQ4;1$14 11:135-1 K),
S, Vilin.i/ MI. Sönmez A. Caglai K. el at Peroxisome prolifera-lor-aclivaicd receptor gamma I I'l'AR-gamma) agonist increases plasma adiponectin levels in type 2 diabetic patients wiili proteinuria. Endocrine 2i)l-5l(>.
Kumada M.
Kihar
a S. Sumitsııji S. el al. Osaka CAD Study Group: Coronary artery disease. Association of hypoadipo-neclinemia with coronary artery disease in men. Arleriosdcr Throntb Vase Bio] 2003;23< 1 1:85-89. s 1 lu i;, Liang I'. Spiegelman IİM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J liiol Chem 1996; 2~U 18): 10697-10703.
9. Kknoyan G. kameire N, Barsi iuni li. et al. The burden of kidney disease: improving global outcomes. Kidney Ini 2004; <>(>i IM3I0-131 I.
10. Go AS, Ghertcra GM, I an I >, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
1lı
iiiebre-Egziabhe
r P. Bernhard J. Funahashi T. 1 ladj-Aissa A, Fouquc I) Adiponectin in chronic kidney disease is related more to mciaholie disturbances than lo decline in renal function. Nephrol Dial Transplam 2Od5;20a):129-134.
12. Yilniaz MI. Sağlam M, Cağlar K. et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (AD-MA) levels alter renal transplantation. Transplantation 2005; S0( 12 >: 1660-1666.
13- Muntner l'. Hamm LL, Kusek J\\ . Chen J, Whelton PK, He.]. The prevalence of nonlnidirional risk factors for coronaiy heart disease in patients with chronic kidney disease. Ann Intern Med 200 i; I-İ0: 9-1".
1 i İkizler TA. Wingard RL, Haneli J, Shyr Y. Hakim RM. ASMKİ-ation of morbidity w ith markers of nutrition am! inflammation in chronic hemodialysis patients: a prospective study. Kidney lnl 1999:55:1945-1951.
15. Iscki K. Tozawa M. Yoshi S. I iikiyama K. Serum C-reaclive protein (GUI') anil risk of death in chronic dialysis patients. Nephrol Dial Transplant [999;l i: 1956-1960.
10. /iminermann J. licrrlinger S. Pruy A. Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney hit I999;55:6 18-658.
I-, liakris lil.. Williams M. Dvvorkin L, et al. Preserving renal function in adulis with Irypertenskwi and diabetes: a consensus
approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36(3>:646-66l.
18. Best PJ. Reddan DN, Berger PB, et al. Cardiovascular disease and chronic kidney disease: insights and an update. Am Heart J 2004;148(2):230-242.
19. Ghiadoni L, Cupisti A, Huang Y, et al. Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol 2004;17(4):512-519.
20. Yilmaz MI, Sağlam M, Cağlar K. et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asyinittet-ric dimethylarginine. Am J Kidney Dis 20<)6;47<11:42-50.
21. Zoccali C, Tripepi G, Cambareri F. et al. Adipose (issue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease palienls. | Ken Nutr 2005;15(1):125-130.
22. Zoccali C, Mallamaci F, Panuccio V, et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Ini Suppl 2003;84: S98-102.
23. Yenicesu M, Yilmaz MI, Cağlar K, el al. Adiponeclin level is reduced and inversely correlated with tlte degree of proteinuria in type 2 diabetic patients. Clin Nephrol 2005;64( 1): 12-19.
24. Saraheimo M, Forsblom G. Fagenidd J, et al. Serum adiponectin is increased in type 1 diabetic patients w ith nephropathy. Diabetes Care 2005;28(6>:l4lO-l4l4.
25. Chudek J, Aciamczak M, Karkoszka II, et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 2O03;35<6>:2186-2189,
26. Koshİmura J. Fujita II, Narita T, el al. Urinary adiponeclin excretion Is increased in palienls with overt diabetic nephropathy. Biochem Biophys Res Commun 2004;316( 11:165¬169.
27. Stenvinkel P. Marchlewska A, Pecoits-I'ilho R, et al. Adiponectin in renal disease; relationship to phenotype ami genetic variation in the gene encoding adiponectin. Kidney Int 2004;65(1):274-281.
28. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among palienls with end-Stage renal disease. J Am Sin' Nephrol 20112:13(1): 134-141.
29- Huang JW, Yen CJ, Chiang HW. Hung KY. Tsai TJ, Wu kl). Adiponeclin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis 2004;43<6): 1047-1055.
30. Lacson EJr, Levin NW. C-reactive protein and end-siage renal disease. Semin Dial 2004;17(6):438-44K.
31. Schalkwijk CG. Chaturvedi N. Schram MI'. Fuller Jll, Stehouwer CD. EURODIAB Prospective Complications Study Group: Adiponectin is inversely associated with renal function in type 1 dial>elic patients. J Clin Endocrinol Metab 2006; 91(11:129-135.

Thank you for copying data from http://www.arastirmax.com